Form 8-K - Current report:
SEC Accession No. 0001178670-25-000038
Filing Date
2025-03-21
Accepted
2025-03-20 18:13:54
Documents
15
Period of Report
2025-03-20
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K alny-20250320.htm   iXBRL 8-K 28284
2 EX-99.1 pressreleaseforcmapproval.htm EX-99.1 46577
6 GRAPHIC image_0.jpg GRAPHIC 8279
  Complete submission text file 0001178670-25-000038.txt   224665

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT alny-20250320.xsd EX-101.SCH 1782
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT alny-20250320_lab.xml EX-101.LAB 22548
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT alny-20250320_pre.xml EX-101.PRE 13046
18 EXTRACTED XBRL INSTANCE DOCUMENT alny-20250320_htm.xml XML 2942
Mailing Address 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE MA 02142
Business Address 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE MA 02142 (617) 551-8200
ALNYLAM PHARMACEUTICALS, INC. (Filer) CIK: 0001178670 (see all company filings)

EIN.: 770602661 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36407 | Film No.: 25758030
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)